drugset / Trial / NCT02587819
Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, open-label, single-arm, multicenter study to assess the safety and tolerability of BSCT (anti-nf-P2X7) 10% Ointment in subjects with BCC.
Timeline
- Start
- 2013-05
- Primary completion
- 2013-10
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-nf-P2X7 | Protein / enzyme biologic | 50 mg | Topical |
| Subject | anti-nf-P2X7 | Protein / enzyme biologic | 100 mg | Topical |